Roche unloads some rights to drug hopeful after asthma trial disappointment

ZURICH (Reuters) - Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments which could total more than $1 billion after the medicine produced only lacklustre results in an asthma study last year.

Source: Reuters: Health - August 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news